Last reviewed · How we verify
NCT07043166
Cardiovascular-Kidney-Metabolic Syndrome in Shanghai Zicitizens
trial in Metabolic Syndrome in 4,094 participants. Currently enrolling.
30 May 2035
Quick facts
| Lead sponsor | Shanghai Changzheng Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 4,094 |
| Start date | 1 July 2025 |
| Primary completion | 30 May 2035 |
| Estimated completion | 31 December 2035 |
| Sites | 1 location across China |
Conditions studied
- Metabolic Syndrome — all drugs for Metabolic Syndrome →
- Diabetes — all drugs for Diabetes →
- Obesity and Overweight — all drugs for Obesity and Overweight →
- Hypertension — all drugs for Hypertension →
Sponsor
Shanghai Changzheng Hospital
Who can join
18 and older, any sex, with Metabolic Syndrome or Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main purpose of this study is to conduct follow-up assessments and update the cardiorenal outcomes among the STONE cohort that was established during 2016-2017. The secondary aim is to compare metabolic risk factors, metabolic disturbances, and clinically relevant metabolic outcomes between the follow-up period and the baseline assessment. The exploratory goal is to examine the relationships between changes in risk factors and clinical outcomes in the participants. The study is planned to begin in May 2025 and will finalize the data collection for the entire population by June 2026. During this time, participants will be categorized based on CKM staging. The follow-up phase will continue until 2035.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Low education and employment status drive cardiometabolic health: a social determinants perspective in Chinese population.
Zhang JF, Cai XY, Tang W, Song Y, et al · · 2025 · PMID 41450524 · DOI 10.3389/fpubh.2025.1676833
Verify or expand the search:
- PubMed search for NCT07043166
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Metabolic Syndrome
Currently open trials in the same condition.
- NCT07501858 — Assessing the Association Between H. Pylori Persistence and the Severity of Insulin Resistance in Patients With Metaboli · recruiting
- NCT06857929 — "Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition" · NA · recruiting
- NCT07237750 — iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss · NA · recruiting
- NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
- NCT07383220 — Effect of Electrical Stimulation and Exercise on Blood Flow in Patients With Resistant High Blood Pressure · NA · recruiting
Other Shanghai Changzheng Hospital trials
Trials by the same sponsor.
- NCT07527884 — The Effect of Radiotherapy After Separation Surgery for Spinal Metastases · NA · not yet recruiting
- NCT07527728 — Postoperative Neurological Recovery and Risk Factor Analysis in Patients With Paralysis Due to Spinal Metastases · not yet recruiting
- NCT07526350 — MTS109 in Patients With Refractory Autoimmune Diseases · EARLY_PHASE1 · recruiting
- NCT07398326 — Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer · Phase 2 · recruiting
- NCT07381257 — Efficacy and Safety of Rifaximin-α in Treating MASLD · EARLY_PHASE1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07043166 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Changzheng Hospital
- Last refreshed: 8 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07043166.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing